Ranbaxy's

To start with, Ranbaxy's Italian operations will exclusively distribute Daiichi's Congescor, a drug to treat heart disease, and high-blood-pressure drug Lopresor to pharmacies in Italy, the Indian generic drug maker said in a statement.

Ranbaxy to Distribute Daiichi Sankyo's Brands in Italy Rumman Ahmed OF Dow Jones Newswires 2011

The blockbuster pill began competing late last year with an authorized copy sold by Watson Pharmaceuticals Inc. and a competing generic from Ranbaxy Laboratories Ltd. The price pressure from a three-way contest—plus since-resolved questions about Ranbaxy's availability—is encouraging health plans to push generics after a slow start, said Everett Neville , chief trade relations officer at Express Scripts.

Express Scripts' Lipitor Move Highlights Pressure on Pfizer Jon Kamp 2012

He said Ranbaxy's quarterly operating margin was weak despite the company benefiting from exclusive U.S. sales of a generic version of Aricept, Eisai Co.'s treatment for Alzheimer's disease.

Ranbaxy's Annual Profit Soars Rumman Ahmed 2011

The analyst estimated that the drug added about $70 million to Ranbaxy's sales in the past quarter.

Ranbaxy Net Profit Slumps 68% Rumman Ahmed 2011

Aarthisundari Jayakumar , an analyst at Alchemy Share & Stock Brokers Pvt. Ltd., said the sales forecast isn't a concern but that Ranbaxy's weak operating performance for the quarter was disappointing.

Ranbaxy's Annual Profit Soars Rumman Ahmed 2011

Three weeks later, the US Food and Drug Administration banned imports of 30 of Ranbaxy's generic drugs, and later determined that the company was selling adulterated or misbranded medicine.

Daiichi Yet to Gain from Ranbaxy Buy Prabha Natarajan 2011

Among the earliest of such deals was Ranbaxy's $4.6 billion sale to Daiichi Sankyo in 2008, which the Singh brothers sold without a banker.

The Unreported Deal Samita Sawardekar 2011

It was unclear when Ranbaxy will be allowed to restart selling drugs manufactured at the two plants, but the FDA settlement and the $500 million provision "bring greater predictability to Ranbaxy's U.S. operations," said Arun Sawhney , Ranbaxy chief executive and managing director.

Ranbaxy Settles With U.S. Regulator Kana Inagaki 2011

Daiichi, after the initial stumbles, seems to now be heading in the right direction and in the past year has integrated Ranbaxy's R&D unit in an effort to gain synergies.

Daiichi Yet to Gain from Ranbaxy Buy Prabha Natarajan 2011

There has been some uncertainty regarding Ranbaxy's ability to launch its product due to heightened regulatory scrutiny.

Stroke Drug to Get Speedy FDA Review Peter Loftus 2011